Publication Venue For
- A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. 2013
- Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. 2012
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. 2012
- Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. 2011
- A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. 2010
- A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. 2009
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. 2009
- O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. 2009
- A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. 2008
- Biomarkers of apoptosis. 2008
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. 2006
- Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. 2006
- Targeted antitumour therapy--future perspectives. 2005
- Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. 2005
- Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. 2005
- Epidermal growth factor receptor tyrosine kinase inhibitors. 2004
- Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. 2004
- Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. 2003
- A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. 2001
- Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours. 2000
- BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. 1999
- Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. 1995
- VAD chemotherapy as remission induction for multiple myeloma. 1995
- A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. 1994